WAS and Wiskott-Aldrich syndrome: In the most recent gene therapy trial for Wiskott-Aldrich Syndrome (WAS) an MLV-based vector backbone expressing the WAS protein was used for transduction of autologous CD34+ HSC which were transfused into two patients.